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microRNAs (miRNAs) play important role in regulating cancer stem cell self-renewal and differen-
tiation, but the expression prolife of miRNAs in glioma stem cells (GSCs) has not been addressed.
Here, we found that CD133 positive GSCs possess a unique miRNAs proﬁle compared to CD133
negative glioblastoma cells. miR-125b, as one of neuronal miRNAs, is the most signiﬁcantly
down-regulated miRNAs and overexpression of miR-125b inhibits the proliferation of CD133
positive GSCs and reduces the expression of ‘‘stem’’ marker. Furthermore, two binding sites for
miR-125b are identiﬁed in the 30UTR of E2F2 and overexpression of miR-125b in CD133 positive GSCs
represses the endogenous level of E2F2 protein. This study demonstrated that miR-125b plays
important roles in regulating the proliferation of GSCs by directly targeting E2F2.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction for maintaining its stemness and escaping the stop signals of cellGlioblastoma is the common type of primary malignant brain
tumors in adult. Despite recent advances in surgery and adjuvant
therapy, treatment of glioblastoma is still a challenging issue in
the clinical setting [1]. Recent studies suggest that many tumors
contain a sub-population of self-renewing and expanding stem
cells known as cancer stem cells (CSCs) [2–4]. In contrast to the dif-
ferentiated tumor cells, CSCs are undifferentiated primitive cells
which maintain their proliferative potential. The CSCs have been
proposed to explain the functional heterogeneity and the carcino-
genesis process of cancer [5,6]. Recently, glioma-derived stem cells
(GSCs) have been isolated from human brain tumors [3,4] and glio-
blastoma cell lines [7]. These GSCs are characterized by their abil-
ity to form neurospheres, undergoing self-renewal, differentiating
into several cell lineages (including neurons, astrocytes, and oligo-
dendrocytes), and generating brain tumors [3,6]. Studies have
shown that GSCs play crucial roles in the development of malig-
nancy of gliomas and are potential targets for therapeutic manipu-
lation [5,8]. However, little is known about the mechanism of GSCschemical Societies. Published by E
Chinese Academy of Sciences,
82898916.
. Cao), linxiukun@yahoo.comdivision.
microRNAs (miRNAs) are short, non-coding RNAs that regulate
the expression of multiple target genes by cleaving or repressing
the translation of target mRNAs. Numerous studies have provided
evidence that miRNAs play the key role in tumorigenesis, cancer
prognosis, diagnosis, and therapy [9,10]. Recent studies have also
revealed that miRNAs play an important role in regulating self-re-
newal and differentiation of stem cell by selectively repressing the
translation of speciﬁc miRNAs [11,12]. However, the expression
characters of miRNAs in GSCs have not been well documented. In
the present study, we investigated the expression proﬁles of cer-
tain miRNAs in GSCs, and tried to ﬁnd the miRNAs which may be
involved in the regulation of GSCs proliferation and differentiation.
miR-125b, a homolog of lin-4, is an important regulator of
developmental timing in Caenorhabditis elegans [13]. miR-125b is
highly expressed in mouse brain and has been implicated in neuro-
nal differentiation of mouse P19 cells by targeting the RNA-binding
protein LIN-28 [14]. miR-125b promotes neuronal differentiation
in human cancer cells by suppressing multiple targets [15]. miR-
125b is also found to be expressed in solid tumors and associated
with cell proliferation and survival [16–20]. However, the function
of miR-125b in the development of GSCs has not been fully docu-
mented. In this study, we investigated the role of miR-125b in
CD133 positive GSCs and our results reveal that there is a lowerlsevier B.V. All rights reserved.
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of miR-125b inhibits the proliferation of CD133 positive GSCs and
reduces the expression of stem cell markers. Further study reveals
that E2F2 gene, a transcription factor of the E2F family, is directly
regulated by miR-125b in CD133 positive GSCs.
2. Materials and methods
2.1. Isolation and culture of CD133 positive glioblastoma stem cells
(GSCs)
Tumor samples were obtained from consenting patients, as ap-
proved by the Research Ethics Board at the Afﬁliated Hospital of
Qingdao Medical University of China. The patients’ information
was listed in Supplementary Table 1. CD133 positive GSCs,isolated
from the tumors as described by Singh et al. [3], and resuspended
in serum free NSP medium consisted of DMEM/F12 medium (Invit-
rogen, CA) supplemented with human recombinant EGF (20 ng/
mL; Sigma, MO), hrFGF2 (20 ng/mL; PeproTech, NJ), B27 (20 mg/
mL; Invitrogen, CA), heparin (10 ng/mL; Sigma, MO) and hrLIF
(10 ng/mL; Chemicon International Inc., CA). NSP culture medium
was refreshed every two days until the spheres of CD133 positive
glioblastoma stem cells (CD133 positive GSCs) were visible under
microscopy. CD133 negative glioblastoma cells were collected
and cultured in DMEM/F12 medium with 10% FBS. After CD133 po-
sitive GSCs were sorted, limiting dilution assay and colon sphere
formation analysis were performed to determine the self-renewal
ability of CD133 positive GSCs, as described by Singh et al. [3].
The details were provided in Supplementary method 1 and 2.
2.2. Differentiation assay of CD133 positive GSCs
The differentiation of CD133 positive GSCs was performed as
described by Singh et al. [3], and the details were provided in Sup-
plementary method 3.
2.3. miRNA microarray and statistical analysis
Human miRNA microarrays (Agilent Technologies, CA) were
used to compare the expression proﬁles of miRNAs in CD133 posi-
tive GSCs and CD133 negative glioblastoma cells. The detailed
method is described in the Supplementary method 4. A median
centered normalization was performed for chip data analysis, toFig. 1. Glioma stem cells (GSCs) formation and differentiation. (A) Primary GSCs spheres w
culture medium (NSP medium) for 7 days. (B) CD133 negative glioma cells exhibit adhes
CD133 (C) and Nestin (D) by immunoﬂuorescence analysis; (E) Cells emigrated from CD1
Immunoﬂuorescence analysis. After the CD133 positive GSCs spheres were cultured in
detect the differentiated cells with Gal-C (F) b-tubulin III (G) and GFAP (H) antigen, respallow comparison among chips and the ratio between CD133 posi-
tive GSCs and CD133 negative glioblastoma cells. Statistical com-
parisons were performed by using the ANOVA (Analysis of
Variance) tool together with the Benjamini and Hochberg correc-
tion for false positive reduction. Clustering analysis was performed
by using Pearson correlation as a measure of similarity.
2.4. Quantitative real-time reverse transcriptation PCR (qRT-PCR)
Real-time RT-PCR analysis was performed as described previ-
ously [21]. The sequences of primers for miR-125b, let-7a and
let-7c are listed in Supplementary Table 2, while the primers of
miR-638 and miR-149 are purchased from Genepharma (Shanghai,
China). The U6 small nuclear RNA used as the loading control was
provided by Genepharma (Shanghai, China). The relative expres-
sion level of mature miRNAs from each sample was calculated
using the 2(-Delta Delta C (T)) Method.
2.5. Cell proliferation and cell cycle analysis
To assess the effects of miR-125b on the growth of CD133 posi-
tive GSCs, cells were transfected with miR-125b duplex (125b-DP,
Dharmacon), negative control miRNA duplex (NC-DP, Dharmacon)
or E2F2 siRNA (On-targetplus SMARTpool L-003260–00-005,
Dharmacon) respectively using Lipofectation 2000 reagent (Invit-
rogen). At certain time points (12, 24, 36, 48 and 72 h, respectively)
after transfection, MTT assay was performed to analyze the cell
proliferation as described previously [21]. To assess the effect of
miR-125b on the CD133 positive GSCs cell cycle, cells were trans-
fected with 125b-DP or NC-DP at the ﬁnal concentration of
100 nM/ml. After having been cultured for 72 h, the cells were
ﬁxed in 70% ethanol, treated with 20 lg DNase-free RNase and
stained with propidium iodide. Cell cycle was then analyzed on a
FACscan (Becton–Dickinson, Fullerton).
2.6. Single cell clone sphere formation analysis
CD133 positive GSCs were dissociated and transfected with
125b-DP and NC-DP as described above. After having been cultured
for 12 h, cells were planted in 96-well plates (10 to 1 cells/well) in
0.2 ml volumes of serum free NSP medium and refreshed each well
every 2 days. The percentage of the wells containing spheres with
more than 100 cells was calculated on day 7.ere observed after the CD133 positive glioma cells cultured in FBS free neurosphere
ion in NSP medium. (C and D) Individual undifferentiated GSCs spheres stained for
33 positive GSCs spheres after cultured in differentiation medium for 3 days. (F–H)
differentiated medium for 7 days, immunoﬂuorescence analysis was preformed to
ectively.
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The full length of 30UTR of E2F2 was PCR ampliﬁed using the to-
tal DNA of CD133 positive GSCs as template and the primers con-
tained the Not1 and Xho1 restriction enzyme sites at the 50end. TheFig. 2. miRNAs proﬁle in CD133 positive GSCs. (A) Unsupervised hierarchical clustering w
GSCs compared to CD133 negative glioblastoma cells. Data anlaysis was performed as
Supplementary Table 1. The color bar represented the grades of the relative expression
Quantitative evaluation of selected 5 miRNAs by real-time PCR. Expression levels of e
analyzed by real time PCR, and presented as log (fold change)±S.D. (nP 3) relative to thPCR products were digested with Not1 and Xho1 and cloned into
the 30UTR of Renilla luciferase of pSICHECK2 (Promega, WI) to con-
struct the Luc-E2F2 construct. Individual wild-type and mutant
MREs (miRNA recognition elementary) were cloned into pSI-
CHECK2 by annealing the forward and reverse oligonucleotidesith bootstrap analysis of 69 selected miRNAs differently expressed in CD133 positive
described in Material and Methods section. Sample numbers were presented in
levels; increase was represented by red while decrease was indicated by green. (B)
ach miRNAs in CD133 positive GSCs and CD133 negative glioblastoma cells were
e levels of U6 small RNA loading control.
Table 1
Differentiated expressed miRNAs in CD133 positive Glioma stem cells(GCSs)
compared to CD133 negative glioblastoma cells.
miRNA Median value of
log2 of CD133
positive GSCs
Median value of log2
of CD133 negative
glioma cells
Fold change
of 1og2
hsa-miR-106b 5.76 12.23 -6.47
hsa-miR-125b 5.76 13.32 -7.56
hsa-miR-9⁄ 6.24 12.20 -5.96
3834 N. Wu et al. / FEBS Letters 586 (2012) 3831–3839containing Not1 and Xho1 sticky end. The sequence of primers and
oligonucleotides used for cloning E2F2 30UTR and MREs were pro-
vided in Supplementary Table 3. The empty vector pSICHECK2 was
used as negative control named as p-NC.
For luciferase reporter analysis, the CD133 positive GSCs were
transfected with miR-125b duplex (125b-DP) or control miRNA
duplex (NC-DP) at the ﬁnal concentration of 100 nM/ml. Luc-
E2F2.p-NC or psiCHECK2 vector containing a single copy of the pre-
dicted MREs or mutated MERs was cotransfected into the cells
(0.5 lg/well) using Lipofectamine 2000 (Invitrogen, CA). After hav-
ing been cultured for another 48 h, luciferase activities were mea-
sured using the Dual Luciferase Assay System (Promega, WI) with
Top count NXT microplate reader (Perkin Elmer, CA) following the
manufacturer’s instructions. Data were normalized to Fireﬂy
luciferase.
2.8. Western blot analysis
CD133 positive GSCs were dissociated by a narrow aspiration
and transfected with 125b-DP, NC-DP or E2F2 siRNA as described
above. After having been cultured for 72 h, cells were collected
and Western blot was preformed to detect the expression of
CD133, Nestin and E2F2 (C-20, SC-633, Santa Cruz Biotechnology,
CA). b-actin (E-5, sc-47778, Santa Cruz Biotechnology, CA) was
used as loading control. The details were provided in Supplemen-
tary method 5.
2.9. Statistics
The statistical analysis of miRNA microarray data was
performed as described in Supplementary method 4. All data were
statistically analyzed using the software from SPSS for Windows
13.0 (SPSS Inc., IL). All data were expressed as mean ± S.D.
Student’s t-test was used to analyze the data signiﬁcance and the
differences were considered statistically signiﬁcant when P < 0.05.hsa-miR-30c 4.25 9.93 -5.68
hsa-miR-361-5p 4.82 10.68 -5.86
hsa-miR-106a 6.09 11.55 -5.46
hsa-miR-93 5.76 11.26 -5.5
hsa-let-7a 3.46 11.51 -8.04
hsa-miR-99a 5.76 11.95 -6.19
hsa-let-7b 3.30 10.13 -6.83
hsa-miR-26a 5.85 13.45 -7.6
hsa-miR-1974 3.48 9.95 -6.49
hsa-miR-100 4.94 11.79 -6.85
hsa-let-7g 3.01 9.17 -6.16
hsa-miR-92b 6.09 11.81 -5.71
hsa-let-7f 2.65 10.40 -7.74
hsa-let-7c 3.30 10.92 -7.62
hsa-let-7d 3.01 10.58 -7.57
hsa-miR-20a 4.82 11.41 -6.59
hsa-miR-9 3.08 9.65 -6.57
hsa-miR-23a 5.16 10.96 -5.8
hsa-miR-92a 4.71 10.30 -5.68
hsa-miR-17 6.17 11.81 -5.64
hsa-let-7e 3.15 9.54 -6.39
hsa-miR-720 7.10 12.85 -5.75
hsa-miR-181a 4.47 10.11 -5.63
hsa-miR-181b 3.64 9.02 -5.39
hsa-let-7i 3.01 9.28 -6.26
hsa-miR-30b 4.03 10.65 -6.62
hsa-miR-16 7.79 14.15 -6.18
has-miR-638 10.06 5.40 4.66
has-miR-149 10.21 3.56 6.66
has-miR-1915⁄ 7.44 2.79 4.65
hsa-miR-637 6.91 3.66 3.25
hsa-miR-438-3P 6.70 3.56 3.14
hsa-miR-758 7.51 3.56 3.95
Note: A median centered normalization was performed for chip data analysis. The
data on column 2 and 3 represented the median of log2 value, while column 4
indicated the data using column 2 minus column 3.3. Results
3.1. Isolation and identiﬁcation of GSCs
CD133 positive glioblastoma cells were separated and cultured
in NSP medium without FBS. After having been cultured for
3–6 days, the majority fractions of CD133 positive stem cells
displayed typical feature of stem cells, forming stem cell spheres
(Fig. 1A). However, the CD133 negative glioblastoma cells exhib-
ited adherence and loss of the ability of proliferation and subse-
quent differentiated (Fig. 1B). Stem cell spheres generated from a
single CD133 positive glioblastoma cell showed immunoreactivity
for the neural stem cell markers CD133 (Fig. 1C) and Nestin
(Fig. 1D). The results suggest that the CD133 positive glioblastoma
cells possess the typical characteristics of glioblastoma stem cells,
namely CD133 positive GSCs.
To further identify the differentiation ability of CD133 positive
GSCs, cells were planted onto poly-L-ornithine coated plate and
supplied with differentiation medium and the differentiation abil-
ity of the CD133 positive GSCs were observed for 7 days. The re-
sults showed that the spheres of CD133 positive GSCs cultured in
differential medium exhibited adherence and some cells started
to emigrate from the sphere at 6 h, and a large amount of cells emi-
grated from the sphere at day 3 (Fig. 1E) and the CD133 positive
GSCs completely differentiated at day 7. The results of immuno-
staining analysis revealed that the differentiated cells could be
stained with antibody of CD133, Nestin, GFAP, GlaC and b-tubulin
III, respectively. Immunocytochemistry analysis also showed that
the differentiated cells could display immunoreactivity forOligodendrocyte maker GlaC (Fig. 1F), neurons marker b-tubulin
III (Fig. 1G) and astrocytes maker GFAP (Fig. 1H). The results
suggest that the isolated CD133 positive GSCs possess the potential
for multi-differentiation.
3.2. Expression proﬁles of miRNAs in CD133 positive GSCs
We then determined the expression proﬁles of miRNAs in
CD133 positive GSCs cells and the CD133 negative glioblastoma
cells (as control) using a miRNA microarray. Total 196 miRNAs
out of 866 arrayed miRNAs in CD133 positive GSCs and 261 miR-
NAs out of 866 arrayed miRNAs in CD133 negative glioblastoma
cells were detected. To identify differentially expressed miRNAs,
the LOWESS ﬁlter analysis was used to remove system related vari-
ations. A list of differentially expressed miRNAs (at P < 0.05) was
generated between CD133 positive GSCs and CD133 negtive glio-
blastoma cells. There were 69 differentially expressed miRNAs
(Fig. 2A) between the CD133 positive GSCs and CD133 negative
glioblastoma cells, in which 30 miRNAs were downregulated and
6 miRNAs were upregulated most signiﬁcantly (Table 1) in
CD133 positive GSCs. Among these miRNAs, all members of let-7
family were downregulated signiﬁcantly and miR-125b is one of
the most signiﬁcantly downregulated miRNAs.
Among 69 differentially expressed miRNAs, ﬁve most signiﬁ-
cantly changed miRNAs, including three downregulated miRNAs
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638 and miR-149), were selected for qRT-PCR analysis to conﬁrm
the reliability as determined by microarray analysis. As shown in
Fig. 2B, the expression of miR-125b, let-7a and let-7c in GSCs
was downregulated with 8.1, 8.0 and 7.5 logarithmized fold,
respectively, while the level of miR-638 and miR-149 was upregu-
lated with 4.68 and 5.67 logarithmized fold, respectively, com-
pared with that of CD133 negative glioblastoma cells (Fig. 2B).
The results of qRT-PCR are consistent with that of the microarray
analysis.
3.3. Overexpression of miR-125b inhibits the proliferation of CD133
positive GSCs
miR-125b was transfected into the CD133 positive GSCs and
the expression level of miR-125b in CD133 positive GSCs was
determined by qRT-PCR. After transfected with 125b-DP, the
expression level of miR-125b was increased more than 50-fold
compared with that in cells transfected with the control miRNA
(NC-DP) (Fig. 3A). Morphological observation revealed that both
size and number of spheres were reduced in miR-125b overex-
pressed CD133 positive GSCs compared with those in the cellsFig. 3. Effect of miR-125b on the proliferation of GCSs. (A) miR-125b expression level in
miRNA mimics (NC-DP) or miR-125b mimics (125b-DP) respectively. After cultured f
expression level of miR-125b to U6 small RNA was presented. (B) After cultured for 3 da
proliferation effect of miR-125b on CD133 positive GSCs. (D) miR-125b overexpression
transfected with 125b-DP or NC-DP. After cultured for 48 h, cells were ﬁxed and stained w
analysis of three independent experiments is shown. (E) Overexpression of miR-125b in
were cultured in NSP medium and transfected with 125b-DP or NC-DP, and planted into 9
formed from single cell were examined by microscope. (F) Tansfection of 125b-DP in CD1
were tansfected with 125b-DP or NC-DP. After cultured for 72 h, cells were collected an
Section 2.transfected with negative miRNA(NC-DP) (Fig. 3B). Moreover,
MTT assay also showed that overexpression of miR-125b resulted
in growth inhibition of CD133 positive GSCs; the cell proliferation
rate was about 55% in the group of CD133 positive GSCs transfec-
ted with NC-DP, while it decreased to 30% in these cells transfec-
ted with 125b-DP as determined at 72 h after transfection
(Fig. 3C), suggesting that miR-125b acts as an inhibitor in regulat-
ing the proliferation of CD133 positive GSCs. Further study
showed that overexpression of miR-125b resulted in a cell cycle
arrest at G0–G1 phase in CD133 positive GSCs (Fig. 3D). The results
suggest that the reduced progression of the cell cycle may, at least
in part, play a role in miR-125b induced proliferation inhibition of
CD133 positive GSCs.
Single cell colony formation analysis revealed that CD133 posi-
tive GSCs transfected with NC-DP could form colony sphere after
cultured in NSP medium for 7 days. However, the cells transfected
with 125b-DP inhibited the proliferation and colony sphere forma-
tion of CD133 positive GSCs (Fig. 3E). The data of Western blotting
showed that miR-125b overexpression reduced the expression of
stem cell markers CD133 and Nestin of CD133 positive GSCs
(Fig. 3F). These results indicate that overexpression of miR-125b
affects the self-renewal ability of CD133 positive GSCs.CD133 positive GSCs. CD133 positive GSCs were transfected with negative control
or 48 h, miR-125b expression level was detected by real-time PCR. The ratio of
ys, the cell growth was observed by microscope. (C) MTT assay to evaluate the anti-
increases the G1 compartment in CD133 positive GSCs. CD133 positive GSCs were
ith propidium iodide and cell cycle was analyzed by ﬂow cytometry. Representative
hibits the single cell colony formation of CD133 positive GCSs. CD133 positive GSCs
6 wells plates with less than 10 cells per well. After cultured for 7 days, cell spheres
33 positive GSCs reduces the expression of CD133 and Nestin. CD133 positive GSCs
d the level of CD133 and Nestin was analyzed by Western blotting as described in
3836 N. Wu et al. / FEBS Letters 586 (2012) 3831–38393.4. E2F2 is directly regulated by miR-125b
E2F2 plays an important role on cell cycle progression, espe-
cially in regulating the progression through G1 phase and is the
putative target of miR-125b. Studies also have shown that E2F2
was downregulated as determined by microarray analysis [15].
We further examined the effect of miR-125b on regulation of
E2F2. CD133 positive GSCs were co-transfected with 125-DP and
E2F2. After having been cultured for 48 or 72 h, the expression
level of E2F2 mRNA or protein of the cells were measured by
qRT-PCR or Western blot, respectively. The results showed thatFig. 4. E2F2 is the directly target gene of miR-125b. (A) Overexpression of miR-125b in C
(B) E2F2 protein is decreased in CD133 positive GSCs transfected with miR-125b. (C) Exp
served as loading control. (D) Predicted binding sites (MRE1–5) in the E2F2 30UTR of m
targeted position in the 30UTR of E2F2. Perfect matches are indicated by a solid line. (E) m
were transfected with control miRNA (NC-DP) or miR-125b mimic (125b-DP) for 48 h an
containing the wild-type (wt) MRE1–5 or control vector (p-NC) were transfected and cul
Effect of mutation of the potential binding sites of miR-125b on E2F2 30UTR (MRE2 and M
that disrupt base pairing of MRE2 and MRE4. (G) miR-125b regulates E2F2 expressio
oligonucleotides (NC-DP or 125b-DP) and luciferase reporters containing the wild-type
was analyzed as described in Section 2. The activity of renilla luciferase was normalized
cells transfected with control miRNA (NC-DP) was deﬁned as 100%. The values represent
t-Test was employed to statistically analyze the results. (⁄⁄)P < 0.01 vs. NC-DP transfecteoverexpression of miR-125b decreased the level of E2F2 mRNA
by 2-fold compared to that of CD133 positive GSCs transfected
with NC-DP (Fig. 4A). The results of Western blot revealed that
E2F2 protein was also decreased obviously (Fig. 4B). Quantitation
assay showed that there was 42% reduction of E2F2 protein in
CD133 positive GSCs overexpressed miR-125b compared to cells
transfected with the negative control miRNA (NC-DP) (Fig. 4C).
To investigate whether the reduced E2F2 was directly mediated
by miR-125b, luciferase reporter system was used to measure
the luciferase activity after co-transfection of miR-125b and E2F2
30UTR luciferase reporter. The results showed that the luciferaseD133 positive GSCs decreases the expression of E2F2 mRNA as analyzed by qRT-PCR.
ression level of E2F2. Densitometry was used to quantify E2F2 protein. b-actin was
iR-125b as predicted by Targetscan. The numbers in parentheses represented the
iR-125b targets the E2F2 30UTR in the luciferase reporter assay. CD133 positive GSCs
d then E2F2 full-length 30UTR-luciferase reporter (Luc-E2F2) or luciferase reporters
tured for another 24 h. Luciferase assay was performed as described in Section 2. (F)
RE4) affects the expression of luciferase activity. Red letters denote point mutations
n by targeting MRE2 and MRE4. CD133 positive GSCs were co-transfected with
(wt) or mutated (mt) MRE2 and MRE4. After incubation for 48 h, luciferase activity
to that of the control ﬁreﬂy luciferase in each experiment. The luciferase activity in
the mean ± S.D. (nP 6) from at least three independent experiments. The two-tail
d controls.
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(Fig. 4E). We next to identify miR-125b binding sites on the E2F2
30UTR using TargetScan6.1 (http://www.targetscan.org) or rna22
(http://cbcsrv.watson.ibm.com/rna22_targets.html) and 5 poten-
tial miR-125b MREs (MRE1 to 5) in the E2F2 30UTR were predicted
(Fig. 4D). The ﬁve predicted MERs were cloned into luciferase re-
porter system and cotransfected with miR-125b respectively. The
results showed that overexpression of miR-125b speciﬁcally and
signiﬁcantly reduced luciferase activity by 2.5 and 1.8-fold in cells
transfected withMRE2 and MRE4 luciferase reporters, respectively,
but had no signiﬁcant effect on luciferase activity with other three
MREs (Fig. 4E). In addition, the inhibition of luciferase activity was
almost abolished when introducing a 4-base mismatch mutation
was introduced into the ‘‘seed’’ region of the MRE2 and MRE4
(Fig. 4F and G). These results indicate that miR-125b is a regulator
of E2F2 in CD133 positive GSCs by binding to the two sites (MRE2
and MRE4) in the E2F2 30UTR.
3.5. miR-125b inhibits the proliferation of CD133 positive GSCs
mediated by direct downregulation of E2F2
Because E2F2 is an important cell-cycle progression regulator,
we next examined the effect of antagonizing miR-125b on the in-
crease of cell proliferation by knocking down E2F2 in CD133 posi-
tive GSCs with co-transfection of miR-125b anti-sense (125b-AS)
(Fig. 5A). Introduction of 125b-AS into CD133 positive GSCs in-
creased cell proliferation for 20% compared to the cells transfected
with the control miRNA anti-sense (NC-AS) (Fig. 5B). However,
knockdown of E2F2 by a speciﬁc siRNA completely abrogated the
proliferative effect of the cells transfected with 125b-AS (Fig. 5B).
Moreover, we also found that overexpression of E2F2 rescued com-
pletely the effects of miR-125b when a E2F2 expression vector
lacking the 30UTR (pE2F2) was delivered into the CD133 positive
GSCs transfected with miR-125b (Fig. 5C and D). The results indi-
cate that downregulation of E2F2 is closely related to the effect
of miR125b on anti-proliferation.Fig. 5. miR-125b inhibits CD133 positive GSCs proliferation by targeting E2F2. (A) Knoc
miRNAs were transfected into CD133 positive GSCs and the level of E2F2 was analyzed
antagonizing miR-125b in CD133 positive GSCs is blocked by siRNA-mediated knockdo
without miR-125b. After cultured for 72 h, the cellular proliferation was determined by M
CD133 positive GSCs is rescued by transfection of E2F2 expression vector without 30UTR
proliferation mediated by miR-125b is rescued by overexpression of E2F2. CD133 positive
duplex (125b-DP) or transfected with E2F2 expression vector lacking 30UTR alone. After c
represent mean ± S.D. from three independent experiments. The two-tail student t-test4. Discussion
In the present study, we found that a total of 69 miRNAs were
differentially expressed between CD133 positive GSCs and CD133
negative non-stem glioblastoma cells, which are isolated from
the same glioblastoma tissues. A vast majority of these miRNAs
were downregulated in CD133 positive GSCs and 30 miRNAs were
downregulated much more signiﬁcantly than others. The results
are consistent with the previous study that majority of differen-
tially expressed miRNAs in normal neural stem cells were down-
regulated in comparison to childhood medulloblastoma [22].
miRNA expression proﬁles reﬂect the state of cellular differentia-
tion, and the studies of miRNA proﬁle in the embryonic stem cells
indicated that both the expression levels and numbers of miRNAs
were kept in low level, however, the level of miRNAs expression
increased as the maturation process progressed towards terminal
differentiation [23].
Notably, of the 30 signiﬁcantly downregulated miRNAs, let-7
family, miR-26a and miR-125b were the most signiﬁcantly down-
regulated miRNAs. We further restricted the analyses of these miR-
NAs to miR-125b because of its important role on cell proliferation
and nerve development [13,15]. Recent studies have shown that
miR-125b regulated mammalian neural stem cell commitment,
and the pool size of the mammalian hematopoietic stem cell
(HSC) [13,14,24]. Studies have also revealed that there are hun-
dreds of predicted targets for miR-125b [15]; Lin28 and Bak1 have
been proposed as the critical targets of miR-125a/b for regulating
the compartments of stem cells [14,24,25]. The function of miR-
125b could be totally different in different cells including human
leukemia, neuroblastoma, and prostate cancer cells [17,18,25–27]
and miR-125b can act as an oncomir by downregulating cell apop-
tosis via repressing Tp53 and Bax1 in some contexts [17,25,27]. On
the other hand, miR-125b could also inhibit the proliferation in a
variety of human cancer cell lines and downregulates cell prolifer-
ation by targeting ERBB2, c-raf and E2F3 in breast cancer, osteosar-
coma and bladder cancer [28–31].k-down of miR-125b up-regulates E2F2 expression in CD133 positive GSCs. Certain
by Western blotting as described in Section 2. (B) Increased cell proliferation from
wn of E2F2. CD133 positive GSCs were cotransfected with certain siRNAs with or
TT assay. (C) The down-regulation expression of E2F2 in miR-125b overexpression
.The expression level of E2F2 was analyzed by Western blotting. (D) Decreased cell
GSCs were cotransfected with E2F2 expression vector lacking 30UTR with miR-125b
ultured for 72 h, the cellular proliferation was determined by MTT assay. Error bars
was employed to statistically analyze the results: ⁄⁄P < 0.01.
3838 N. Wu et al. / FEBS Letters 586 (2012) 3831–3839In the present study, we found that the expression of miR-125b
was signiﬁcantly decreased in CD133 positive GSCs and ectopic
expression of miR-125b in CD133 positive GSCs inhibited the cell
proliferation. Recent study by Shi et al. also found that miR-125b
was critical in regulating the proliferation of CD133 positive U251
cells and upregulation of miR-125b expression induced growth
inhibition of CD133 positive U251 cells [19], which is consistent
with our ﬁnding. However, other studies showed that miR-125b
could promote cell proliferation and inhibit ATRA-induced cell
apoptosis in human U343 and U251 glioma cells [18]. In the present
study, Western blot analysis was performed to determine the
expression of miR-125b targeted genes, and the preliminary results
showed that TP53, bcl2 and CDKs were signiﬁcantly decreased in
CD133 positive glioblastoma cells (data not shown), suggesting that
the inhibitory effect of miR-125b mediated by these cell prolifera-
tive genes cannot be functioned in CD133 positive cells. In addition,
there is evidence to show thatmiR-125b could act as a buffer to reg-
ulate the target genes’ dosage in different contexts [27].
Our data of cell cycle analyses showed that miR-125b inhibited
the proliferation of CD133 positive GSCs by inducing cell cycle ar-
rest at the G1 phase, and these ﬁndings are consistent with previous
report that miR-125b is necessary for stem cell ﬁssion to bypass the
normal G1/S checkpoint, making the stem cells insensitive to che-
motherapy [13,32]. E2F2, a member of the E2F family of transcrip-
tion factors plays a central role in regulating G1/S transition and
progression through S phase, promoting cellular transformation
[33]. Inhibition of E2F2 expression arrests cell division in G1 phase.
We can assume that miR-125b regulates cell-cycle progression of
CD133 positive glioblastoma cells via miR-125b mediated E2F2.
Several miRNAs have been found to target E2F2, including miR-
17–92 cluster [34] and miR-24 [35]. However, no differentiated
expression of miR-17–92 cluster and miR-24 was found in the
present study. Therefore, the effect of miR-125b mediated on
E2F2 plays a key role in the proliferation of CD133 positive glio-
blastoma stem cells. Our present study provides evidence for the
ﬁrst time to show that the expression levels of miR-125b in glio-
blastoma stem cells are signiﬁcantly lower than that of non-stem
glioblastoma cells and overexpression of miR-125b inhibits the
proliferation of glioblastoma stem cells by directly targeting
E2F2. Our study also reveals that dysregulation of this miRNA
may play a role in gliomagenesis.
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